INVESTOR ALERT: Class Action Lawsuit Against Galectin Therapeutics Inc. Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of purchasers of the securities of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ:GALT) between January 6, 2014 and July 28, 2014, inclusive (the “Class Period”).

Galectin is a development stage company engaged in the research and development of therapies for fibrotic disease and cancer. The Complaint alleges that defendants misrepresented or failed to disclose that the Company paid a stock promotions firm for a misleading promotional campaign touting Galectin stock, and that the Company’s experimental drug GR-MD-02, which was being developed for the treatment of fatty liver disease, showed little difference from a placebo in its Phase 1 study.

If you are a member of the Class described above, you have until September 29, 2014, to move the Court to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.